摘要
目的探讨应用血管紧张素转化酶抑制剂（ACEI）和（或）血管紧张素受体拮抗剂（ARB）联合安体舒通治疗IgA肾病患者，观察其降低尿蛋白及肾脏保护作用。方法将54例IgA肾病患者随机分为安体舒通组（A组）27例，对照组（B组）27例。A组在应用ACEI和（或）ARB基础上联合安体舒通20mg／d；B组按原量服用ACEI和（或）ARB药物。检测2组在第0、4、8、12、16周时24h尿蛋白、血肌酐、血钾、血浆醛固酮、血压、估算肾小球滤过率（eGFR）。结果A组治疗后第8周时尿蛋白较治疗前下降18．5％（P〈0．05），至第16周时下降35．1％（P〈0．01）；B组至治疗终点仅下降5．3％，无统计学差异（P〉0．05）。2组血钾、血肌酐、eGFR、血浆醛固酮、血压较治疗前无显著变化（P〉0．05）。结论在应用ACEI和（或）ARB基础上联合安体舒通对降低kA肾病患者尿蛋白有显著作用。
Objective To observe the effect of antisterone on urine protein and renal function after antisterone was added to the patients who were treated with ACEI and/or ARB. Methods The patients with IgA nephropathy were randomly divided into antisterone group and control group. Patients in control group were treated with ACEI and/or ARB, and those in antisterone group were treated with antisterone （20 rag/day） besides ACEI and/or ARK The 24-h urine protein, serum ereatinine, serum potassium, plasma aldosterone, blood pressure and eGFR were measured at the 0, 4th, 8th, 12th, and 16th week after the treatment. Results （1） At the 8th and 16th week, urine protein was statistieally lower than that before the treatment in the antisterone group, and the dropping rate was 18. 5% （P〈0. 05） and 35.1% （P〈0. 01） ,respectively. In the eontrol group there was no statistical decrease during the treatment （P〉0. 05）. There were no significant differences in serum creatinine, eGFR, blood pressure, serum potassium and plasma aldosterone in both two groups （P〉0. 05）. Conelusions Antisterone plus ACEI and/or ARB eould significantly reduce the urine protein in patients with IgA nephropathy.
出处
《临床肾脏病杂志》
2011年第10期454-456,共3页
Journal Of Clinical Nephrology
